Here Is What the Results Show
FDA’s new pilot for one day inspectional assessments is worth understanding clearly, because the actual results are more instructive than the headlines suggest.
Here is what FDA reported as of late April 2026. The agency completed approximately 46 one day assessments across human and animal foods, biologics, medical products, and clinical research programs. Most resulted in No Action Indicated outcomes.
Facilities that were running well held up well, even under a short, focused assessment. That is the real message.
The pilot is designed for lower risk establishments, selected using risk based criteria including product type, prior inspection outcomes, and operational characteristics. FDA is using operational and compliance data to support more targeted, risk based oversight decisions.
The one day format is not intended to replace standard inspections. It is an additional tool to expand surveillance coverage and gather data to inform future oversight.
Where organizations should pay attention is the flexibility built into the design. Some assessments extended beyond one day when investigators identified significant observations. A short assessment can still surface a real problem, and investigators retain authority to expand scope or duration if warranted.
One record can lead to a CAPA. One CAPA can lead to an investigation. One investigation can reach a supplier, a procedure, a training record, a batch record, or a management decision.
The organizations that come out of focused assessments with NAI outcomes are not simply the ones with polished inspection binders. They are the ones running quality systems that hold up on any given day.
That is what continuous readiness actually looks like. Not a war room. Not a binder sprint. Systems that work. Records that are retrievable. CAPAs that are genuinely closed.
If your organization wants to pressure test where you stand, that is the work Medvacon does with quality teams.